The serine‐threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells

Conclusions and ImplicationsThe targeting of p90RSK by enzastaurin represents a new therapeutic option for the treatment of follicular lymphoma.

Source: British Journal of Pharmacology - November 14, 2013 Category: Drugs & Pharmacology Authors: S Kheirallah, S Fruchon, L Ysebaert, A Blanc, F Capilla, A Marrot, T AlSaati, F X Frenois, K A Benhadji, J J Fournié, G Laurent, C Bezombes Tags: Research Paper Source Type: research